ASP7991
Phase 1CompletedDevelopment Stage
Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy
Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy, Pharmacodynamics of ASP7991, Pharmacokinetics of ASP7991
Dec 26, 2012 โ Jun 26, 2013
About ASP7991
ASP7991 is a phase 1 stage product being developed by Astellas Pharma for Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy. The current trial status is completed. This product is registered under clinical trial identifier NCT01872026. Target conditions include Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy, Pharmacodynamics of ASP7991, Pharmacokinetics of ASP7991.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01872026 | Phase 1 | Completed |
Competing Products
20 competing products in Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + Epoetin beta | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| PLX3397 + Temozolomide | Daiichi Sankyo | Phase 1/2 | 41 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| ASP8825 | Astellas Pharma | Phase 1 | 33 |
| ASP015K | Astellas Pharma | Phase 1 | 33 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 77 |
| ATG-F | Astellas Pharma | Approved | 85 |
| Celecoxib | Astellas Pharma | Pre-clinical | 23 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| ASP1585 | Astellas Pharma | Phase 2 | 52 |